Finding inhibitors for PCSK9 using computational methods

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the key targets for atherosclerosis drug development as its binding with low-density lipoprotein receptor leads to atherosclerosis. The protein-ligand interaction helps to understand the actual mechanism for the pharmacological action....

Descripción completa

Detalles Bibliográficos
Autores principales: Zainab, Rida, Kaleem, Afshan, Ponczek, Michał B., Abdullah, Roheena, Iqtedar, Mehwish, Hoessli, Daniel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341581/
https://www.ncbi.nlm.nih.gov/pubmed/34351937
http://dx.doi.org/10.1371/journal.pone.0255523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341581/
https://www.ncbi.nlm.nih.gov/pubmed/34351937
http://dx.doi.org/10.1371/journal.pone.0255523

Ejemplares similares